Smoking, tobacco addiction and current treatment options

Česká verzia

Authors: Z. Perná; M. Vašáková
Authors place of work: Primářka: doc. MUDr. Martina Vašáková, Ph. D. ; Fakultní Thomayerova nemocnice s poliklinikou ; Přednosta : prof. MUDr. Jiří Homolka, DrCs ; Pneumologická klinika 1. LF UK Praha
Published in the journal: Prakt. Lék. 2009; 89(12): 679-683
Category: Of different specialties

Summary

Tobacco addiction is one of the chronic diseases mentioned in 10th International statistic classification of diseases under the diagnosis code F 17. This article summarises information about tobacco, history of smoking, contents of cigarette smoke and its harmfulness, current options and strategies for the treatment of tobacco addition. It also touches on the rising problem of smoking amongst children and teenagers. According to the data from the National Health Institute the sale of cigarettes or tobacco was not refused to 80% of smokers aged between 13 and 15; and 30% of boys and 25% of girls aged sixteen smoked daily. There are 28 specialized centres for the treatment of tobacco addiction in the Czech Republic. They work at the level of professional non-pharmacological, pharmacological and psychobehavioural help for individuals addicted to the tobacco.

Key words:
cigarette smoke, addition to tobacco, strategy of treatment of tobacco addition.

Zdroje

1. Gonzales, D., Rennard, S.I., Nides, M. et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296, p. 47-55.

2. Jorenby, D.E., Hays, J.T., Rigotti, N.A. et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained -release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296, p. 56-63.

3. Klesges, R.C., Johnson, K.C., Somes, C. Varenicline for smoking cessation. Definite promise but no panacea. JAMA 2006, 296, p. 94-95.

4. Králíková, E. Nový lék závislosti na tabáku: vareniclin, parciální agonista α4β2 acetylcholin-nikotinových receptorů. Čas. lék. čes. 2006,145, s. 832-834.

5. Králíková, E., Býma, S., Cífková, R. a kol. Doporučení pro léčbu závislosti na tabáku. Čas. lék. čes. 2005, 144, s. 327-333.

6. Oncken, C., Gonzales, D., Nides, M. et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 2006, 16, p.1571-1577.

7. Tonstad. S., Tonnesen, P., Hajek, P. et al. Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296, p. 64-71.